Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could, may, might, if pigs could fly, then maybe Avanex could possibly get approval for indications before any controlled study is completed. That pump has not worked. Now what is Dr Missleading going to do next.
ROTFLMAO If NTRP would have spent 5 years running a uncontrolled study they could be two years away from having meaningful results. Yes, Dr Missleading has only spent $100m to get to the point of running a controlled trial. Glad NTRP is not that stupid.
Yes Merck has a knack for picking losers. They did the same thing Anavex is doing and failed. Failing with the mild to moderate AD patients they started a P3 trial with the same failed drug on just Mild AD patients and failed again. AVXL 2 year trila will fail but Dr Missleading is hoping for a stock pump, so far no luck.
Last year the pump was Biogen, this year it is Merck, maybe next year it will be Amazon wanting to sell 2-73 on line.
You fogot gout and the vapors, classic snake oil ailments.
Of course not, they already know it does not work. But that is what snake oil salesmen do, they just change the label to another ailment.
"Anavex is not working on proving 2-73 for Alzheimer's."
None of which validates the wishful thinking and speculation that somehow a drug with no valid trial is going to get AD approval in the middle of a 2+ year blinded trial. Just looks like an elaborate pump job to me. But that is the history of Anavex, over commit under deliver and pump the stock.
I agree they are motivated. Looks like they think Prana
Bio is a better bet. They have given them a lot more money over the last two years than Anavex.
"Bottom line, Australia is motivated to get an effective treatment: "
Obviously the market does not believe any of this. The only way this happens is if there is fraud, which is not unheard off in AUS or with Anavex. No one believes Dr Missleading no matter how much he pumps. Pure speculation and wishful thinking.
LOL, all we have heard is how MJFF and Australia are paying for the trials. They were 2 years late on getting the trials going what were they doing then. Dr Missleading is taking care of no 1.
The poor AVXL retail investors are being taken to the cleaners, they are spending 2x more than NTRP is spending per qtr and all they got so far is constant dilution and no results.
Who knows who is being paid what in AUS. It is funny that it is claimed that they are paying for the trials
yet Dr Missleading spent over $7m last qtr, looks like someone is being paid off.
Avanex is counting on the luck of the con artist, NTRp is counting on the science 2-73 has been around for over 20 years and has yet to a complete single valid trial. It has been used to scam a multitude of retail investors.
LOL more BS from Dr Missleading? Sounds like a pump to me.
"The results from the Parkinson's trial could be strong enough for Anavex to gain provisional approval in Australia before the end of the year. "
Who cares about 2-73, the bottom line is it is a scam. Snake oil is readily available.
Yes difficult but not a problem. If you would have actually read the article the answer is in black and white. Note the words solution and economical below.
Here, we report a solution to the bryostatin 1 supply problem in the form of a step-economical, multigram-producing synthesis that addresses both clinical and research needs and serves additionally as a practical platform for accessing new and potentially superior analogs. Our convergent synthesis proceeds in 29 steps, with a longest linear sequence (LLS) of 19 steps and 4.8% overall yield (>80% average yield per step), and has collectively produced >2 g of bryostatin 1. All steps, except the final step for safety reasons, were conducted on a gram to multigram scale. This synthesis can thus readily supply the amount of material needed to further advance clinical evaluation, as a single gram of bryostatin 1 can treat ~1000 cancer patients (9, 11) or ~2000 Alzheimer’s patients (4) according to currently used clinical dosing.
The more the pro AVXL posts on here the more convinced I am that it is a scam and desperation. Plenty of proof of that but when a company has to ride on the back of another company that has done what no other company has, it speaks for itself. There is nothing that AVXL has done in a valid trial to justify that they will succeed and the constant promotion is really big red flag.
PS: if any body is thinking about buying any AVXL, wait a little while it is going to get a whole lot cheaper before it goes up. Then you can sell on the next pump.
What you posted is not the total truth, they can do it up to 200% at their discretion, retail investors are being ripped off by Dr Missleading who does no one any good by hiding things.
The S3 is pretty clear and if the company was legit it would publish the schedule of its sales of stock to a questionable company like LCP.
What is unfounded is how wrong you are. The actual agreement in the company S3 states that the company can increase the amount purchased by 200% if it chooses, so there is no 50,000 share limit.
Of course Dr Missleading is not going to provide a list of days and amounts. Last fiscal year they sold 2.4m shares of stock at an average price of $3.40. Lets see when those purchases happened and how much LCP made on the deal at the end o the year, not as they are happening.
"LCP shares are doled out 50,000 at a time. It would be absurd to publicly announce each mini offering. "
Looks like he worked at Forest Labs with the CEO, that's where namenda was developed and marketed. Also he is the COO, my guess he will be working the oral and synthetic versions and getting the manufacturing up and running.
Avxl and LCP is classical retail investor ripoff. Why dont they show the dates of purchase and sale. LCP only holds enough stock to sell when it goes up and gets to buy at the lows. Dr Missleading is probably getting a kickback. That is the cabal that controls the stock price.
If LPC AVXL deal is legit prove it. Let's see all of their AVXL transactions, they are known as a retail investor ripoff company.
https://www.ripoffreport.com
LINCOLN PARK CAPITAL Ripoff Reports, Complaints, Reviews, Scams, Lawsuits and Frauds Reported
Your Search: Lincoln Park Capital
There may be more reports for "Lincoln Park Capital"
For more results perform a general search for "Lincoln Park Capital"
Showing 1-3 of 3 Found Reports For more results perform a general search for "Lincoln Park Capital"
Wondering if a report is missing? We DO NOT remove reports.
Specific Search General Search
1, Report #1082103 Jun 24 2014
04:35 PM
Lincoln Park Capital Fraud, Scam, Failure to Fund Chicago Illinois
Author: Alberta
2, Report #1118130 May 08 2014
09:02 AM
Lincoln Park Capital Joshua Scheinfeld, Jonathon Cope Alleging Investigation Reveals Numerous Lawsuits Alleging Extortion, Racketeering in Organized Crime Act, Upfront Fee S...Show more
The AVXL stock scam with LCP is well documented.
"In the Purchase Agreement LPC expressly agrees to engage in “no short selling or hedging” of AVXL common stock, but in my opinion if one look closely, one detail of the transaction purposefully allows LPC to do exacly that.
Purchase Agreement filed with the SEC 10/26/2015
With the execution of the “Purchase Agreement” Anavex agreed to issue LPC 179,958 newly issued shares for free. LPC can now use these free shares in their account as a “float” to sell shares in the market in advance of the shares they will purchase later at a discounted price(the lowest quoted price of the day), effectively engaging in a transaction akin to shorting the shares they will cover via purchase later, while on paper it can be claimed that LPC is transacting from a long position.
One can imagine a scenario like this, LPC starts the day with the full balance of the 179,958 free shares, during that day they sell in the open market at various price points 50,000 shares, end with a balance of 129,958 shares; at the end of the day they go to Anavex that issue them 50,000 new shares at the lowest quoted price of the day and the balance is replenished to 179,958 shares, LPC can now repeat the same transaction the next day, effectively shorting the stock with the appearance of being a long seller."
Boy if I had invested in AVXL, I would really be worried. These are all the things that AVXL claims to solve, Plus they target the same MCI patients that AVXL is restricted to.
BTW the AVXL expose' was not from the motley fool. That
article documented their scam stock sales. Sorry not even close to accurate.
I can understand the confusion, one cannot compare the Avxl trual that ran a non placebo MCI trial of 32 patients where 7 patients dropped out. To a real AD trial of 100 moderate to severe patients where 17 placebo dropped out and 15 of the treated dropped out who were also on namanda.
If I was an Avxl investor I would wonder why so many MCI patients dropped out of the AVXL scam trial.
By definition it would have to be a subjective investor, because if they deny Dr Alkon's hard per reviewed data they are not objective.
"Not according to the objective investor apparently"
There are so many red flags with that stock. They spend over 2x more per qtr and they issue stock to LCP like candy. Why would they be selling stock for less than $3.00 when they claim they have enough cash for all their trials. Avxl Stockholders are really bagholders.
Burg, that is a great idea, let's get runcoach to look in to all the possible reasons the trial might fail. We could call his posts the Xcoachfiles.
It is pretty simple, there have been 150 trial failures over the past few years. Most people do not do due diligence and follow the crowd. That is why overhyped stocks get large market caps. Look at Axovant, they had a 2+ billion cap starting a P3, their science was bad their stock went from $25 to $1.30.
So based on your logic, they were a good investment because their marketcap was high.
The reason that NTRP dropped was because their initial release of their data (that they and others saw as good) were viewed as disappointing to investors. Dr Alkon in his interview goes over that in detail saying it was a mistake because the results when fully analyzed were phemonenal.
https://soundcloud.com/levine-media-group/company-seeks-to-prove-marine-derived-alzheimers-drug-is-no-fish-story
So most investors follow the crowd and believe the BS posted on msg boards. In order to make smart investments DD is required and honest people that look at Dr Alkon, the research and results are as confident as they can be that it's chances for success are greater than any out there.
Ta Da we have a winner. Who would have thought that results matter. The only results that matter to this board is NTRP. So far no one has come close and no one will confirm results sooner.
That explains even more why it is a 2 year trial with MCI patients. Dr Misleading found another foil. Ya and everybody knows that taxpayers never get ripped off LOL.
"It's Australian taxpayer money being spent so I can assure you it is not a scam per the TGA."
To bad for Anavex, they got nothing to take to the party for 2 years. ANd then they find out they failed.
"The EU is preparing a massive Alzheimer's trial initiative: "
No I am suggesting that Anavex will fail any placebo based trial unless they again "mine for data". Also with their past history of buying stock promotions there is a great chance that they are playing games here also. It also ties into the 2 years before meaningful results and their Toxic financing with LPC.
BTW their Anavex-AUS company web site in AUS is recruiting for the trial.
Also why would they need Tax cuts, they are not close to making a penney of profit. LOL
Again no lies below is the documented truth.
Your argument was that it was MCI not AD
The selection criteria requires confirmed plaque either by spinal fluid assay or PET. PET is most used now and the criteria clearly indicates that this qualification can be met during the selection process.
As posted earlier it does not require it it says if the results are available it can be submitted.
NTRP chooses the criteria for its trials, why shouldn't Anavex?
NTRP uses an world renown company WCT to do the trials. Anavex has a shill company it owns doing the selection
Your own post confirms that we are talking about MCI Alzheimer's confirmed.
"It’s estimated that about 20 percent of people over the age of 70 have MCI. Generally, as people age, they are more likely to develop MCI as well as Alzheimer’s disease.
MCI is often thought of as the period between normal cognition and when Alzheimer’s disease develops. Others consider it to be an actual early stage of Alzheimer's, although not everyone with MCI will develop Alzheimer’s."
Also, by including patients up to 28 a significant nunber could be considered normal.
Scoring of the MMSE
Scores on the MMSE range from 0 to 30, with scores of 25 or higher being traditionally considered normal. Scores less than 10 generally indicate severe impairment, while scores between 10 and 19 indicate moderate dementia."
Given Anavex's history of paying for promotions, all of thes items lead one to conclude this trial should not be trusted. Of course there will be no results for 2 years anyway.
LOL - using words out of context does not turn lies int fact. The fact that the trail criteria does not require a PET, the fact that the criteria choosing group is an Aavex controlled entity and the fact that the MMSE is from 20-28 means that no investor should trust anything that Anavex does on this trial would lead them to believe that this is a trust worthy AD trial.
It focuse on MCI patients.
So you are saying the inclusion info on the trial website in incorrect. It clearly does not require a PET scan. So yes to tell investors that it is would IMO be fraud.
Inclusion Criteria:
Patients aged 60 to 85 years, inclusive, with a NIA-AA diagnosis of mild cognitive impairment (MCI) due to AD or early stage mild dementia due to AD. AD diagnosis should be made by an appropriately qualified medical specialist and AD pathology should be confirmed by either:
Historical records of amyloid CSF assessment or
Historical records of amyloid PET scan or
If neither historical records are available, then AD pathological diagnosis confirmation should be offered at screening:
BR, the way that you sell snake oil is to treat people that are not sick with a remedy that does little or nothing. The success of AVXL has to do with selling the story that it actually does something.
So now you admit it is a MCI trial, the only thing to fess up on is that the PET is not a requirement. It would be fraud to entice applicants to apply that did not have a PET and then tell them they are not accepted. Also a MMSE of 28 is ridiculous for a trial for AD, that is why the trial is not about AD.
"I have posted and documented all of this before. This discussion is redundant. "
Not the fact that you post something does not make it true.
Not true, the trial does not require PET, the AUS Corp is the one running the trial and a MMSE requirement of 20-28 is clearly MCI. The company documents the trial one way then claims something else in public. No one should trust the scam.
The two dinky trials in Spain and US are to pump up the SP so LCP can cleanup their final $11m in dilution. The AUS MCI trial due in 2+ years is a sham. It controlled by a Anavex puppet company so they can make sure they don't get any real AD patients taking the drug.
How would you know? The facts stand for themselves. Anavex even has a sham AUS organization controlled by them managing the flawed MCI trial. I am sure that is why they can only run the trial in AUS.